{"product_id":"anti-cd19-car-t-cells-bhc18200254","title":"Anti-CD19 CAR-T Cells","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table tr:nth-child(even) th{background:#dce8fb}\n.bhp-desc .bhp-spec-table tr:nth-child(even) td{background:#f0f6ff}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600;margin-bottom:10px}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-license-box{background:#f5f5f5;border:1px solid #ddd;border-radius:4px;padding:12px 16px;font-size:14px;color:#444;margin:10px 0 14px}\n.bhp-desc .bhp-regulatory-row{display:flex;gap:16px;flex-wrap:wrap;margin:6px 0 10px}\n.bhp-desc .bhp-reg-item{background:#f0f6ff;border:1px solid #ccd9f0;border-radius:4px;padding:6px 12px;font-size:14px}\n.bhp-desc .bhp-reg-item strong{color:#003366;display:block;font-size:12px;text-transform:uppercase;letter-spacing:.5px}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eScientific Background\u003c\/h2\u003e\n\u003cp\u003eCD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, which is a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19\/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed\/refractory B-precursor ALL (Acute lymphoblastic leukemia). In addition, CD19 was the target of the first approved CAR-T cell therapy.\u003c\/p\u003e\n\u003ch2\u003eProduct Description\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eCAR-T\u003c\/span\u003e\n\u003cp\u003eThe anti-CD19 CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ; SIN Vector, BPS Bioscience, #78601). These ready-to use CAR-T cells express an anti-CD19 CAR consisting the ScFv of CD19 (clone FMC63) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.\u003c\/p\u003e\n\u003ch2\u003eProduct Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTransfection Method\u003c\/th\u003e\n\u003ctd\u003eLentivirus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSupplied As\u003c\/th\u003e\n\u003ctd\u003eEach vial contains 2 x 10\u003csup\u003e6\u003c\/sup\u003e cells in 1 ml of CryoStor® CS10)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHarmonized Tariff Code\u003c\/th\u003e\n\u003ctd\u003e3002-5900\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eQuality Control \u0026amp; Validation\u003c\/h2\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✓ Mycoplasma-Tested\u003c\/span\u003e\n\u003cp\u003eThe cells have been screened to confirm the absence of Mycoplasma species.\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cp style=\"margin:0 0 4px\"\u003e⚠ Avoid freeze\/thaw cycles. Donors have been screened and determined negative for: - Hepatitis B (anti-HBc EIA, HBsAg EIA) - Hepatitis C (anti-HCV EIA) - Human Immunodeficiency Virus (HIV-1\/HIV-2 plus O) - Human T-Lymphotropic Virus (HTLV-I\/II) - HIV-1\/HCV\/HBV - West Nile Virus - Trypanasoma cruzi Note: Testing cannot guarantee that any sample is completely virus-free. These cells should be treated as potentially infectious and appropriate biological safety level 2 precautions should be used.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch2\u003eRegulatory Information\u003c\/h2\u003e\n\u003cdiv class=\"bhp-regulatory-row\"\u003e\n\u003cdiv class=\"bhp-reg-item\"\u003e\n\u003cstrong\u003eLicense Required\u003c\/strong\u003eNo\u003c\/div\u003e\n\u003cdiv class=\"bhp-reg-item\"\u003e\n\u003cstrong\u003eLiving Modified Organism\u003c\/strong\u003eYes\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2\u003eLicense Disclosure\u003c\/h2\u003e\n\u003cdiv class=\"bhp-license-box\"\u003eTroubleshooting Guide: For all further questions, please email support@bpsbioscience.com.\u003c\/div\u003e\n\u003ch2\u003eRelated Products\u003c\/h2\u003e\n\u003cp\u003eRelated Products: Cat. #90184-A, 60690, 79714, 78170\u003c\/p\u003e\n\u003c\/div\u003e","brand":"BPS Bioscience","offers":[{"title":"1 Vial","offer_id":53322322575725,"sku":"78171-1","price":1595.0,"currency_code":"USD","in_stock":true},{"title":"5 Vials","offer_id":53322335715693,"sku":"78171-2","price":4250.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/78171_2.png?v=1778636472","url":"https:\/\/www.ebiohippo.com\/products\/anti-cd19-car-t-cells-bhc18200254","provider":"BioHippo","version":"1.0","type":"link"}